6 news items
Aligos Therapeutics Presented Poster Highlighting The Continued Potent Antiviral Activity Of ALG-000184 For Chronic Hepatitis B (CHB) In Both Hbeag-Positive And Hbeag-Negative Subjects At The EASL Congress 2024
ALGS
5 Jun 24
Aligos Therapeutics Presents Positive Data at the EASL Congress 2024
ALGS
5 Jun 24
for chronic hepatitis B (CHB) in both HBeAg-positive and HBeAg-negative subjects. Data from ≤72 weeks following an oral daily dose of 300 mg ALG
Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024
ALGS
22 May 24
: ALG-000184: Potential best-in-class small molecule CAM-E for chronic hepatitis B (CHB
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
ALGS
7 May 24
multiple cohorts of untreated chronic hepatitis B (CHB) patients receiving once daily doses of ALG-000184 as monotherapy or in combination with entecavir
Aligos Therapeutics Presents Clinical Data At APASL 2024 From ALG-055009 And ALG-000184 Phase 1 Studies
ALGS
27 Mar 24
ALG-000184: Potential best-in-class small molecule CAM-E for chronic hepatitis B (CHB
8qsk982993zg5pdhzmbxu32mkyxfceddvlt6cbfvodbg
ALGS
27 Mar 24
-000184: Potential best-in-class small molecule CAM-E for chronic hepatitis B (CHB) Oral Presentation
- Prev
- 1
- Next